Rolf Sass Sørensen was appointed Chief Executive Officer of TETRAPHARM effective October 6, 2026, succeeding co-founder Martin Rose who established the company with Jesper Breum in 2018. TETRAPHARM advances novel drug molecules and proprietary drug development delivery technologies alongside its contract development and manufacturing (CDMO) services.
Sørensen brings more than 30 years of experience, including senior roles in investor relations and corporate communications. He previously served as Vice President Investor Relations & Communications at Bavarian Nordic, where he held the position from 2010. Before Bavarian Nordic, Sørensen worked at Nordea Bank ABP as an analyst in 2006. His experience includes knowledge of the life sciences sector and the relationship between biotechnology companies and capital markets.
Career history
- Chief Executive Officer, TETRAPHARM (October 2026-present)
- Vice President Investor Relations & Communications, Bavarian Nordic A/S (2010-2026)
- Analyst-Equity, Nordea Bank ABP (2006)
What Rolf Sass Sørensen could bring to TETRAPHARM: Sørensen's three-decade career in investor relations and corporate communications at Bavarian Nordic positions him to enhance TETRAPHARM's capital markets strategy and stakeholder engagement. His deep knowledge of biotech-investor dynamics and life sciences sector dynamics should accelerate the company's ability to attract funding, communicate its scientific achievements, and execute its drug development and CDMO service roadmap.
Facts compiled by Executive Moves from publicly available news and press releases on 9 October 2026. Spotted an inaccuracy? Email us and we'll review within 1 business day.
To upgrade to a Premium Profile reach out to us at info@executive-moves.com.
Are you Rolf Sass Sørensen?
This is a Light profile, auto-generated from public news coverage. Claim it to verify your bio, add a photo and links, and control how your career is represented on Executive Moves.
Claim this profile →
